Early diagnosis of CMV infection based on sensitive diagnostic assays has helped to reduce CMV-related mortality after allogeneic stem cell transplantation (SCT). In this study, the commercialized Murex CMV DNA Hybrid Capture assay (version 2.0) (HCS) was prospectively compared to an in-house CMV-DNA PCR assay from whole blood in patients after allogeneic stem cell transplantation. Overall, a high concordance between HCS and PCR was documented (kappa = 0.686; n = 385). The HCS assay was found to be as sensitive as the PCR indicating active CMV infection at a median of 35 and 34 days after transplantation, respectively. None of the HCS-negative patients developed CMV-related symptoms (negative predictive value 100%). Declining CMV DNA load in the blood was found to be an indicator for effective antiviral therapy, whereas persistence of a high viral load was associated with fatal CMV disease. In conclusion, the Hybrid Capture CMV DNA assay (v 2.0) allows early diagnosis of CMV infection after allogeneic SCT and assessment of the efficacy of antiviral therapy. Bone Marrow Transplantation (2001) 28, 213-218. 
Cytomegalovirus infection remains a major cause of morbidity and mortality in patients after allogeneic stem cell transplantation (SCT). [1] [2] [3] [4] Preemptive antiviral therapy based on pp65 antigenemia and CMV-DNA PCR assays has been shown to reduce CMV disease and CMV-associated mortality following allogeneic SCT. [5] [6] [7] [8] [9] [10] Thus, preemptive CMV-directed antiviral therapy based on sensitive detection methods has become a standard of care in many transplant centers. A major drawback of this approach is a lack of standardization of the diagnostic assays used for early detection of CMV infection. 11 More recently, sensitive diagnostic tests based on the detection of CMV-specific nucleic acid sequences have been commercialized. [12] [13] [14] [15] [16] [17] The Murex Hybrid Capture CMV DNA assay (version 2.0) (HCS) is a solution hybridization antibody capture assay for the quantitative detection of CMV DNA in leukocytes. The first generation HCS assay proved to be useful for early diagnosis and monitoring of antiviral therapy in AIDS patients and solid organ transplant recipients. 15, [17] [18] [19] However, the sensitivity of the assay was too low to safely monitor patients at high risk for CMV infection after allogeneic SCT. 13 In this study, the second-generation HCS assay was prospectively compared to an in-house CMV-DNA PCR assay for early diagnosis of CMV infection after allogeneic SCT and for monitoring the efficacy of antiviral therapy.
Patients and methods

Patients
Forty-one consecutive patients (median age, 40 years; range, 17 to 56 years) were treated with myeloablative therapy followed by allogeneic stem cell transplantation (Table  1) . Twenty patients received a transplant from a matched unrelated and 21 patients from an HLA-identical sibling donor. Fifteen of these 21 patients received peripheral blood stem cells and six bone marrow. Preparative regimens were assigned according to clinical treatment protocols. All patients underwent a preparative regimen that included either 12 Gy of accelerated fractionated total body irradiation (TBI) (2 Gy twice a day for 3 consecutive days, lung shielding 10 Gy) or 16 mg/kg body weight (bw) busulfan. Cyclophosphamide 2 × 60 mg/kg (bw)/day was infused following TBI (TBI/Cy) or busulfan (Bu/Cy). Donor marrow or peripheral blood stem cells were infused on day 0. Patients with advanced disease received an intensified conditioning regimen, either TBI/Cy plus etoposide (40 mg/kg bw) or plus thiotepa (2 × 5 mg/kg bw) each administered on day −4.
GVHD prophylaxis consisted of cyclosporine A (CsA) according to serum levels plus antithymocyte globulin (ATG) given on days −4 to −2 in 25 patients. In addition to this combination, nine patients receiving a transplant from an unrelated donor were treated with mycophenolate mofetil and corticosteroids starting on day 7 after transplantation. Seven patients at high risk for relapse of the underlying disease received CsA as single agent for GVHD prophylaxis. CD34 + selection of peripheral blood stem cells from related donors using the CellPro device was performed in nine patients.
Oral acyclovir was administered at a dose of 400 mg four times a day for prophylaxis of herpes simplex virus infection until day 60 post transplantation. All CMV-seropositive patients (n = 19) as well as CMV-seronegative patients receiving a transplant from a CMV-seropositive donor (n = 6) received blood products unscreened for CMV, whereas all CMV-seronegative patients receiving a transplant from a CMV-seronegative donor (n = 16) received CMV-seronegative blood products. Informed consent was obtained from all patients, according to the declaration of Helsinki.
Therapy for CMV infection and CMV disease
All patients were screened once weekly for signs of active CMV infection by HCS, CMV-DNA PCR, and conventional as well as rapid virus culture assays from whole blood, starting on the day of transplant until day 100 post transplantation. Preemptive antiviral therapy with ganciclovir (2 × 5 mg/kg bw) or foscarnet (2 × 60 mg/kg bw) was initiated within 24 to 48 h from the time of the second consecutive positive PCR result as previously described. 8 HCS results were not considered for clinical decision making and not reported to the attending physicians. Patients with documented CMV disease received combination therapy with ganciclovir and CMV-hyperimmunoglobulin as reported before.
1,4 Antiviral treatment was stopped after 14 days if clearance of the virus was documented by PCR. Maintenance therapy with ganciclovir (6 mg/kg bw per day 5 times weekly) or foscarnet (90 mg/kg bw per day 5 times weekly) was only administered if PCR remained positive after a 14-day course of antiviral therapy.
Diagnosis of CMV disease
CMV disease was diagnosed according to the criteria defined by the Fourth International Cytomegalovirus Workshop in Paris 1993. 20 A diagnosis of CMV pneumonia required dyspnoea, interstitial infiltrates on the chest radiograph and a positive CMV culture of a bronchial washing. CMV enteritis required gastrointestinal symptoms and the demonstration of CMV by histology or immunohistology, and CMV hepatitis required abnormal liver function tests, typical histological changes and the detection of CMV in the liver biopsy by culture or DNA hybridization.
CMV-DNA PCR
DNA extraction of 5 ml EDTA-anticoagulated blood was performed as previously reported. 6 A 147-bp DNA fragment between position 1767 and 1913 of the fourth exon of the immediate early gene of the human CMV strain AD169 was amplified by PCR with specific primers (5Ј-AGCTGCATGATGTGAGCAAG, 5Ј-GAAGGCTGAGTT CTTGGTAA) as described before. 7 In all assays, amplification of 0.1, 1, 10 and 100 fg of the cloned human CMV-DNA fragment pCM5018 was included. 21 Amplicons were detected by slot blot hybridization using a CMV-specific, digoxigenin-labeled oligonucleotide (5Ј-GGGTGCACT GCAGGCTAAGGCCCGTGCTAAAAAGGATGAA) and anti-digoxigenin antibodies, labeled with alkaline phosphatase (Roche, Mannheim, Germany). The detection limit of the assay was 0.1-1 fg CMV-DNA.
Virus culture
For virus culture, human foreskin fibroblasts were inoculated for 45 min at 37°C with 0.2 ml of a leukocyte suspension (1 × 10 6 cells). Growth of CMV was identified by the appearance of characteristic cytopathic effects on fibroblasts. In a separate identically inoculated culture, CMV immediate early antigens were detected 48 h after inoculation by an indirect peroxidase technique using the monoclonal antibody E13 (Biosoft, Paris, France). Subsequent incubation with peroxidase-conjugated immunoglobulin (Dako, Hamburg, Germany) and with the chromogen aminoethylcarbazol (Sigma, St Louis, MO, USA) yielded brown nuclear staining of infected cells.
Murex Hybrid Capture CMV DNA assay (v 2.0)
The Hybrid Capture assay was provided by Murex Diagnostica (Burgwedel, Germany). DNA was extracted from 3.5 ml EDTA anticoagulated blood with the use of the manufacturer's lysis solution and tubes. Thereafter, the CMV-specific RNA probe was added and the tubes were incubated for 2 h at 70°C. The RNA-DNA hybrids were transferred to specific antibody-coated capture tubes that were placed on a rotary shaker for 60 min. After incubation with an alkaline-phosphatase-conjugated antibody specific for RNA-DNA hybrids, the colorimetric substrate was added and the samples read with a luminometer. CMV-DNA was quantified by comparing the relative light units (RLU) of the samples to the RLU of a calibration standard curve. A ratio of sample RLU to the positive cutoff value of Ͼ1.0 was considered to indicate a positive test result according to the manufacturer's instructions.
Statistical evaluation
Statistical evaluation was performed as follows: after log transformation (in order to stabilize the variance) groups were compared with ANOVA. Post-hoc tests of pairwise comparisons were performed according to the TukeyKramer procedure.
Results
Detection of CMV infection
Overall, 385 blood samples were analyzed by HCS, CMV-DNA PCR and culture methods. Test results were 90.1% concordant between PCR and HCS and a high measure of agreement was documented (kappa = 0.686; s.e. = 0.047; n = 385). Eighty-two samples were found PCR positive and 68 samples HCS positive. Twenty-six samples were PCR positive but HCS negative, and 12 samples were HCS positive but PCR negative. Additionally, seven out of 385 blood samples were found culture-positive. All culture-positive samples were also found positive by PCR, and six of seven by the HCS assay.
Three hundred and fifty-four samples obtained from 41 weekly monitored patients (mean 8.6 samples per patient, range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were used for the longitudinal analysis. Twenty-three samples from 17 patients tested only once or twice as well as eight samples from one patient treated with ganciclovir already at the time of transplantation were excluded from analysis. CMV infection was diagnosed by PCR in 19 of 41 patients at a median of 35 days (mean, 35.8 days; range, 2-90 days), by HCS in 22 of 41 patients at a median of 34 days (mean, 38.5 days; range, 16-84 days), and by viral blood culture in six of 41 patients at a median of 59 days (mean, 62 days; range 48-81 days) post transplantation ( Table 2) . None of the 16 CMV-seronegative patients transplanted from a seronegative donor was found to be PCR positive, and only one patient developed a single positive HCS result. Thus, a specificity of 100% (95% CI: 96.2-100%; n = 95) was documented for the PCR and of 98.9% (95% CI: 94.3-100%; n = 95) for the HCS assay.
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Preemptive antiviral therapy
Nineteen patients received PCR-based preemptive antiviral therapy until day 100 and all patients were correctly identified by the HCS assay. Four of these 19 patients developed CMV-related symptoms at the time of the second consecutive positive PCR result (CMV interstitial pneumonia, n = 3; CMV hepatitis, n = 1). Additionally, one PCR-negative but HCS-positive patient developed CMV-induced interstitial pneumonia. The false negative PCR result was related to genome mutations of the primer binding site at positions 1768 (G→A), 1771 (G→C), 1772 (C→T), and 1775 (G→A) (Hamprecht et al, unpublished) . Three patients recovered from CMV disease under combination therapy with ganciclovir and CMV hyperimmunoglobulin, while two patients died. Two PCR-negative patients, who never showed any clinical sign of CMV infection developed one positive HCS result each (1421 and 2197 genomes/ml).
Assessment of the viral load
In two patients with fatal CMV disease, the highest viral peak titers as measured by the HCS assay were documented (191 500 and 507 223 genomes/ml), when compared to three patients with non-fatal CMV disease (22 249, 30 987, and 46 136 genomes/ml, respectively) and patients with asymptomatic CMV infection (n = 15; mean, 19 296; range, 1183-118 164 genomes/ml) (Figure 1 ). Peak titers of viral DNA preceded the onset of CMV-related symptoms in four of five patients (Table 2) . PCR positivity persisted for a mean of 1.75 (range 1-7) weeks and HCS positivity for a mean of 1.45 (range 1-7) weeks after initiation of antiviral therapy. Despite antiviral therapy, the two patients with fatal CMV disease showed persistence of a high viral load, whereas all other patients showed clearance of the viral DNA from the blood after 1 to 7 weeks of antiviral therapy (Figure 2 ).
In addition, viral peak titers as assessed by the HCS assay were higher in patients receiving a bone marrow graft from a matched unrelated donor (n = 10; mean 106 707; range, 7099-507 223 genomes/ml), compared to patients receiving allogeneic peripheral blood stem cells from related donors (n = 8; mean, 15 441; range, 1183-48 656 genomes/ml) (P Ͻ 0.05).
Discussion
CMV infection remains a major cause of infection-related morbidity and mortality after allogeneic SCT. Preemptive antiviral therapy based on sensitive detection methods has helped to reduce the incidence of CMV disease and CMVrelated mortality until day 100 post transplantation. 5, 8 The Murex Hybrid Capture CMV DNA assay (v 2.0) is a quantitative hybridization assay with improved sensitivity compared to the first-generation test. 16 In this study, the HCS assay was prospectively compared to an in-house CMV-DNA PCR assay. The HCS assay demonstrated a high sensitivity and specificity for early diagnosis of CMV infection, and a high concordance between the two methods was reduce antiviral treatment to patients at higher risk to develop CMV-related symptoms. In recipients of solid organ transplants and in patients with AIDS, CMV-related symptoms were found to be associated with a high viral load in the blood. 17, 22, 23 In comparison, viral loads were found to be significantly lower in recipients of an allogeneic stem cell transplant, even in patients with CMV disease. Thus, studies applying less sensitive techniques to quantify the CMV-DNA load in leukocytes did not detect differences in viral loads between patients with symptomatic and asymptomatic CMV infection. 23 In the study reported, the highest peak titers of CMV-DNA as assessed by HCS (v 2.0) were found in the two patients with fatal CMV disease.
Three patients with non-fatal CMV disease showed overlapping titers, compared to patients with asymptomatic CMV infection (Figure 1 ). Viral peak titers preceded the onset of CMV-related symptoms in four out of five patients. However, the viral load in the blood in patients with CMV disease varied widely, indicating, that factors apart from viral load in the blood seem to determine the development of CMV disease. Nevertheless, prospective monitoring of the viral load may provide important information on the dynamics of viral replication in individual patients. 24 Thus, replication dynamics might correlate more closely with the risk of CMV disease than the absolute viral load in a given patient. A higher CMV DNA load was detected in patients receiving a transplant from a matched unrelated donor, a group known to be at an increased risk for CMV disease when compared to patients receiving a transplant from a matched sibling donor. 2 Reconstitution of CMV-specific T cell immunity was found to be markedly delayed in patients receiving a transplant from a matched unrelated donor compared to patients grafted from a matched sibling donor. 25, 26 In addition, the stem cell source was reported to influence the kinetics of immune reconstitution.
CMV-DNA PCR has been shown to allow to monitor the efficacy of antiviral therapy. 7, 8 In this study, patients with fatal CMV disease showed persistence of a high viral load in spite of antiviral therapy. In contrast, all patients surviving CMV disease or receiving PCR-based therapy at the second consecutive positive PCR result without clinical signs of CMV infection cleared the viral DNA from the blood within 1 to 7 weeks after initiation of antiviral therapy. Thus, the study reported supports the concept of drug monitoring by quantitative assessment of the CMV DNA load in clinical samples. 9, [27] [28] [29] Future studies may prospectively evaluate the HCS assay in comparison with other quantitative CMV detection methods, such as the COBAS Amplicor CMV monitor test 30, 31 in patients following stem cell transplantation.
In conclusion, according to our experience, the Hybrid Capture CMV DNA assay (version 2.0) is a sensitive detection method for CMV-DNA in blood samples, that allows early diagnosis of CMV infection and monitoring of the efficacy of antiviral therapy in patients after allogeneic stem cell transplantation.
